CHEMBL1991 Target Snapshot

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Inhibitor of nuclear factor kappa-B kinase subunit beta shows late clinical disease relevance led by Autosomal dominant polycystic kidney disease. 5 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt O14920. Start with Autosomal dominant polycystic kidney disease, then reuse UniProt O14920 as the stable protein anchor across project notes and exports.

Review focus

Review-ready target frame

Start with Autosomal dominant polycystic kidney disease, then reuse UniProt O14920 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 1 linked drug

Open source guide

Disease program

Autosomal dominant polycystic kidney disease

Inhibitor of nuclear factor kappa-B kinase subunit beta shows late clinical disease relevance led by Autosomal dominant polycystic kidney disease. 5 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.

Start review with Autosomal dominant polycystic kidney disease because it currently carries late clinical support. Linked drugs include BARDOXOLONE METHYL. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy

Late clinical Open Targets-ready proxy 1 linked drug

Open disease block

Protein anchor

Inhibitor of nuclear factor kappa-B kinase subunit beta

Review this target as Inhibitor of nuclear factor kappa-B kinase subunit beta, mapped to UniProt O14920. Sequence length is 756 aa.

Protein source · UniProt accession via ChEMBL component mapping

UniProt O14920 Protein 756 aa

Open protein block

Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Inhibitor of nuclear factor kappa-B kinase subunit beta as ChEMBL target CHEMBL1991, mapped to UniProt O14920. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor

Inhibitor of nuclear factor kappa-B kinase subunit beta

SINGLE PROTEIN · Homo sapiens

As of 2026-09-13

ChEMBL target ID

CHEMBL1991

Primary anchor for compounds, assays, approvals, and exports

ChEMBL 36 via Core Engine As of 2026-09-13

www.ebi.ac.uk

UniProt accession

O14920

Inhibitor of nuclear factor kappa-B kinase subunit beta

UniProt accession via ChEMBL component mapping As of 2026-09-13

www.uniprot.org

Disease evidence contract

Open Targets-ready proxy

ChEMBL drug mechanism + indication proxy

ChEMBL drug mechanism + indication proxy As of 2026-09-13

www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?

UniProt Target Context

UniProt accession via ChEMBL component mapping

Start here when your first question is whether Inhibitor of nuclear factor kappa-B kinase subunit beta is the right protein anchor across sources, using UniProt O14920 as the stable mapping.

Jump to Protein Context

Need disease fit before discussing compounds?

Disease Relevance & Evidence Level

ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why Autosomal dominant polycystic kidney disease is currently framed as late clinical support. It currently carries 1 linked drug in the same disease frame.

Jump to Disease Context

Need a meeting-ready explanation of why this target matters?

Evidence Card

Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card

Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred Name	Inhibitor of nuclear factor kappa-B kinase subunit beta
Target Type	SINGLE PROTEIN
Organism	Homo sapiens
UniProt	O14920

ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein Label	Inhibitor of nuclear factor kappa-B kinase subunit beta
UniProt Accession	O14920
Component Type	Protein
Sequence Length	756 aa

Inhibitor of nuclear factor kappa-B kinase subunit beta

Source · UniProt accession via ChEMBL component mapping Freshness · Sep 14, 2026, 8:09 AM KST As of · Sep 13, 2026

UniProt Context ↗

Review Cue

How to read this target

Review this target as Inhibitor of nuclear factor kappa-B kinase subunit beta, mapped to UniProt O14920. Sequence length is 756 aa.

Mapped IDO14920

Review nameInhibitor of nuclear factor kappa-B kinase subunit beta

OrganismHomo sapiens

Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Late clinical Open Targets-ready proxy

Inhibitor of nuclear factor kappa-B kinase subunit beta shows late clinical disease relevance led by Autosomal dominant polycystic kidney disease. 5 more disease programs remain visible in the same review block.

Late clinical Phase III

Autosomal dominant polycystic kidney disease